Andrew Hollman Meyer sold $107k of JANX
Chief Business Officer at Janux Therapeutics, Inc.. 3,334 shares at an average of $32.15, traded Mar 3, 2025, filed Mar 5, 2025.
Score components
- +15RoleOfficer
- +10Trade size$107k at market
- 0Share of holdings soldSold 3.9% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-007104, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2025 | MOption exercise Common Stock10b5-1 | +3,334 | $4.21 | $14k | 85,473 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -2,433 | $31.88 | $78k | 83,040 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -901 | $32.85 | $30k | 82,139 | Mar 5, 2025 |
| Mar 3, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,334 | $0.00 | $0 | 93,999 | Mar 5, 2025 |
Related signals
Other insiders at Janux Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $107k 3,333 shares | -4% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $100k 3,334 shares | -4% | |
| 43Moderate | JANXbuy Janux Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $25M 824,041 shares | +9% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $141k 3,334 shares | -4% | |
| 27Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $300k 5,000 shares | -2% | |
| 29Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $732k 13,334 shares | -14% | |
| 43Moderate | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.4M 25,000 shares | -10% | |
| 30Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.0M 15,000 shares | -6% | |
| 30Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.3M 25,000 shares | -9% | |
| 38Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.3M 25,000 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.